Diagnostics and Screening
An Introduction to Diagnostics and Screening
Early detection of tumours is essential to increase the likelihood of complete remission. Screening strategies are not without risk; for example, mammography and prostate-specific antigen screening can lead to the detection of indolent lesions and subsequent overtreatment. Precision medicine has improved screening and diagnostic approaches; tumour-typing of breast tumours for oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 has informed treatment options. Many non-invasive diagnostic tools can be used directly at the point of care. It is hoped that advances in the genomic classification may lead to the identification of high-risk individuals in other types of cancer.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Diagnostics and Screening Content
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Following a scientific primer, the role of radiopharmaceuticals in the management of neuroendocrine tumours and prostate cancer, alongside approaches to support clinical implementation, are explored by leading experts.
- Describe the underlying rationale and mechanism of action for radiopharmaceuticals in adult oncology
- Recall the different types of radiopharmaceuticals (approved and in clinical development), and their specific properties
- Summarize the latest efficacy and safety data available for radiopharmaceuticals in the management of adult solid tumours, including potential implications for current and future clinical practice
- Propose strategies to support integration of radiopharmaceuticals into adult oncology pathways to individualize clinical management, and ultimately, optimize patient outcomes
Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
Three experts discuss the burden and clinical presentation of pyruvate kinase deficiency, as well as current and emerging therapeutic strategies.
- Recognize the signs and symptoms of PK deficiency and the burden of disease in affected patients
- Evaluate established therapeutic strategies for PK deficiency and identify remaining unmet treatment needs
- Describe novel and emerging therapeutic strategies for PK deficiency and how they may address current unmet needs
Facing clinical challenges associated with paroxysmal nocturnal haemoglobinuria
Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.
- Summarize the signs and symptoms of PNH and how these inform the clinical diagnosis
- Explain the benefits and limitations of current and emerging complement inhibitor therapies for PNH
- Explain the burden of PNH and impact on patients’ quality of life
Targets, Therapies and the Role of Serial Biopsies for Prognostication and Assessing Changes to Tumour Biology in Oesophageal and Oesophagogastric Junction Cancers
touchREVIEWS in Oncology & Haematology. 2022;18(2):107-12 DOI: https://doi.org/10.17925/OHR.2022.18.2.107
Cancers of the oesophagus and oesophagogastric junction (OGJ), termed upper gastrointestinal (UGI) cancers, are lethal and constitute a significant public health problem. In 2020, 604,000 cases and 544,000 UGI cancer-related deaths were estimated worldwide.1 UGI cancers are the seventh most frequently diagnosed cancer and the sixth most common cause of cancer-related death.1 In the USA, there were […]
Advancing the multidisciplinary management of rare and unusual NETs: Integrating new approaches to treatment and care
Watch leading specialists involved in the multidisciplinary care of patients with rare and unusual neuroendocrine tumours discuss new and emerging approaches for diagnosis and treatment.
- Recognize the role of the MDT in addressing diagnostic and treatment challenges associated with rare and unusual neuroendocrine tumours (NETs)
- Evaluate the factors guiding treatment selection and clinical management decisions in rare and unusual NETs
- Appraise the efficacy and safety of new and emerging treatment options for rare and unusual NETs
New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identification and novel treatment strategies
Watch leading breast cancer specialists share their perspectives on risk stratification and future therapies in HR+ HER2- early breast cancer.
- Apply appropriate risk assessment and stratification strategies to predict patients’ likely risk of disease recurrence
- Evaluate the latest guidelines and treatment options for the management of high-risk HR+ HER2- early breast cancer and assess the remaining unmet need
- Interpret the evidence for novel therapeutic options for high-risk HR+ HER2- early breast cancer
Personalized treatment of RET-altered thyroid cancers: What is the value of biomarker testing and targeted therapies?
Leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
- Distinguish between different types of thyroid cancers and describe therapies that are appropriate for their management
- Plan a personalized approach to treatment of RET-altered thyroid cancers, including use of biomarker testing and novel targeted therapies
- Evaluate the clinical trial data for novel targeted therapies for RET-altered thyroid cancers and apply it to clinical practice
Implementing a personalized approach to treatment of thyroid cancer: the importance of biomarker testing and targeted therapies
Watch leading specialists within an MDT discuss the importance of biomarker testing and targeted therapies for personalizing management of thyroid cancer
- Distinguish between different types of thyroid cancers and identify appropriate therapies for their management
- Plan for the use of precision medicine in thyroid cancer, including implementation of biomarker testing and use of novel targeted therapies
- Evaluate the clinical trial data for novel targeted therapies for thyroid cancer and translate it into clinical practice
Criteria for Evaluating Multi-cancer Early Detection Tests
touchREVIEWS in Oncology & Haematology. 2021;17(1):3-6 DOI: https://doi.org/10.17925/OHR.2021.17.1.3
Somatic DNA mutational analysis has transformed how we characterize existing cancer and select treatments. For example, circulating tumour cell-free DNA (cfDNA) can be used to select targeted therapies, monitor treatment response and detect disease recurrence.1 However, early attempts with targeted sequencing of circulating tumour cfDNA to screen for multiple cancers were unsuccessful because of low sensitivity […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!